Morphosys Email Format

Biotechnology Research
501-1,000 employees
Planegg, Bavaria, Germany

MorphoSys is a German biotechnology company specializing in the discovery and development of innovative antibody-based therapeutics for patients with serious diseases worldwide.

Find contacts at Morphosys

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@morphosys.com

Company Overview

Industry
Biotechnology Research
Founded
1992
Headquarters
Planegg, Bavaria, Germany
Revenue
$250M-$500M
FUNDING Stage
Public

Tech Stack

Salesforce

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Morphosys?

Morphosys uses the first.last format on morphosys.com, so Jane Smith would be jane.smith@morphosys.com.

What approved drug is Morphosys best known for in oncology?

Morphosys is best known for Monjuvi (tafasitamab), an FDA-approved monoclonal antibody targeting CD19, used in combination with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who are not eligible for autologous stem cell transplant.

How can I find a specific Morphosys contact for outreach or prospecting?

With around 185 employees spread across Planegg, Germany and Boston, Massachusetts, Morphosys has a fairly compact team. Tools like Clay can help you verify a specific contact's email or identify the right person within a particular function before reaching out.

Does Morphosys have a US office, and where is it located?

Yes, Morphosys operates a US subsidiary called MorphoSys US Inc., based in Boston, Massachusetts, which has supported the commercial and clinical operations for the company's oncology programs in North America.

Where does pelabresib fit in the Morphosys pipeline?

Pelabresib is a BET inhibitor that Morphosys gained through its acquisition of Constellation Pharmaceuticals, targeting myelofibrosis. It was a central asset in Novartis's decision to acquire Morphosys for approximately 2.7 billion euros in 2024.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles